The company was launched by serial entrepreneur Charles Homcy and venture capital firm Third Rock Ventures in 2012 to tackle a disease that mainly affects Black and Hispanic communities and had been largely spurned by drug developers for decades.
The company was launched by serial entrepreneur Charles Homcy and venture capital firm Third Rock Ventures in 2012 to tackle a disease that mainly affects Black and Hispanic communities and had been largely spurned by drug developers for decades.
